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Tumor heterogeneity at the genetic level has been illustrated by a multitude of studies 
on the genomics of cancer, but whether tumors can be heterogeneous at the metabolic 
level is an issue that has been less systematically investigated so far. A burning-related 
question is whether the metabolic features of tumors can change either following natural 
tumor progression (i.e., in primary tumors versus metastasis) or therapeutic interventions. 
In this regard, recent findings by independent teams indicate that antiangiogenic drugs 
cause metabolic perturbations in tumors as well as metabolic adaptations associated 
with increased malignancy. Induced metabolic bioluminescence imaging (imBI) is an 
imaging technique that enables detection of key metabolites associated with glycolysis, 
including lactate, glucose, pyruvate, and ATP in tumor sections. Signals captured by 
imBI can be used to visualize the topographic distribution of these metabolites and 
quantify their absolute amount. imBI can be very useful for metabolic classification of 
tumors as well as to track metabolic changes in the glycolytic pathway associated with 
certain therapies. Imaging of the metabolic changes induced by antiangiogenic drugs in 
tumors by imBI or other emerging technologies is a valuable tool to uncover molecular 
sensors engaged by metabolic stress and offers an opportunity to understand how 
metabolism-based approaches could improve cancer therapy.
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inTRODUCTiOn
Malignant tumors are endowed with distinct metabolic features that distinguish them from the 
normal cells of the tissue where they arise. Major metabolic alterations in tumors include enhanced 
glucose uptake and lactate production, increased glutamine utilization and de novo fatty acid 
synthesis, as well as aberrant choline and serine metabolism (1, 2). Tumor heterogeneity  –  best 
known at the genetic level – has recently been illustrated also at the metabolic level by a number of 
different approaches (3, 4). Still largely unknown is whether metabolic features of tumors are stable 
Abbreviations: H&E, hematoxylin and eosin; HIF, hypoxia inducible factor; imBI, induced metabolic bioluminescence imag-
ing; NMR, nuclear magnetic resonance; PET, positron emission tomography; VEGF, vascular endothelial growth factor.
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or can change either following natural tumor progression (i.e., in 
primary tumors versus metastasis) or therapeutic interventions.
Antiangiogenic therapy is a consolidated approach to treat 
cancer. By targeting the tumor-associated microvasculature, 
antiangiogenic drugs – especially blocking signaling downstream 
of vascular endothelial growth factor (VEGF)/VEGF recep-
tors  –  cause vessel pruning, which is followed by hypoxia and 
reduced supply of other nutrients (5–8). Since antiangiogenic 
drugs do not have, in general, direct effects of tumor cells; the 
therapeutic activity of these drugs is almost entirely dependent 
on modulation of the supportive functions of the tumor micro-
environment. Albeit still hypothetical, it is quite possible that the 
ability of tumor cells to adapt to the starving effects of antiangio-
genic therapy – i.e., its metabolic effects – could be important to 
determine the therapeutic activity of these drugs.
Imaging techniques are extremely valuable both to perform 
metabolic profiling of tumors and to uncover metabolic fluc-
tuations caused by drugs. With regard to antiangiogenic therapy, 
some of these techniques have been used to measure uptake of 
selected metabolites in tumors, such as positron emission tomog-
raphy (PET) (9), whereas others, including hyperpolarized 13C 
spectroscopy (10) and proton nuclear magnetic resonance (NMR) 
(11), enabled quantitative assessment of certain metabolites in 
experimental tumors.
We were the first to exploit a technique termed induced meta-
bolic bioluminescence imaging (imBI) to investigate metabolic 
perturbations associated with anti-VEGF therapy (9, 12). Notably, 
although somewhat limited by the small number of metabolites 
that can be analyzed, imBI provides an accurate representation 
of the steady-state levels of the metabolites, matching them to 
the histology of the tumor section. The rest of this chapter is 
devoted to the methodologic description of this valuable imaging 
technique and its applications in the field of tumor angiogenesis.
THe TeCHniQUe FOR inDUCeD 
MeTABOLiC BiOLUMineSCenCe 
iMAGinG
Specific Detection of Tissue Metabolites
The imBI technique was developed in the laboratory at the 
University of Mainz for the detection of metabolites in cryosec-
tions from snap-frozen tissue in  situ (13–15). Self-made kits 
containing definite exogenous enzymes and cofactors are used 
to achieve high specificity and sensitivity. Endogenous enzyme 
activities in the tissue sections of interest are heat-inactivated 
immediately before imBI measurement to avoid interference with 
exogenous enzymes within the kit. To prevent the reactions from 
substrate saturation, all components of the kit are provided in 
excess. The enzymatic activity induced by the metabolite of interest 
in the target tissue is biochemically coupled to luciferases leading 
to light emission, i.e., to bioluminescence. This coupling, which 
involves the NAD(P)H+H+ redox system, induces low level light 
emission with an intensity that is proportional to the respective 
metabolite. The biochemistry for the detection of ATP, glucose, 
pyruvate, and lactate via imBI is illustrated diagrammatically in 
Figure S1 in Supplementary Material. Since a specific enzyme 
mixture has to be prepared for each metabolite of interest, the 
imBI technique allows for the detection of only one metabolite 
per  section. On the other hand, section thickness is adjusted 
in most cases to values in the range of 10–20 μm, and thus 
different metabolites can be determined in serial sections at a 
quasi-identical location within a tissue.
For processing of the tissue specimens, the frozen biopsy is 
embedded in Tissue-Tek® (O.C.T.™ Compound; Sakura Finetek 
Europe B.V., Alphen aan den Rijn, Netherlands) on a sample 
holder of a cryomicrotome (SLEE cryostat, Type MEV; SLEE, 
Mainz, Germany). Serial sectioning is then performed precisely 
at a temperature between −20 and −12°C depending on the tissue 
composition of the specimen. As indicated in the upper panel of 
Figure 1A, two parallel channels are driven into each biopsy by a 
specially designed “micro-fork.” Sectioning perpendicular to these 
channels leads to two holes in each section. These holes make it 
possible to precisely overlay sequential sections and, thus, to colo-
calize different parameter values in different adjacent sections.
Localization of Tissue Metabolites
The spatial resolution of imBI is generated by a sandwich technique 
providing a homogeneous contact between enzyme cocktail and 
tissue section (Figure 1A). An excess volume of enzyme solution 
is pipetted into a casting mold within a metal slide. A cover glass 
with a tissue section adhered is laid upside-down onto the enzyme 
solution within the casting mold. This provides complete contact 
between tissue and enzyme solution, which has been kept in a 
liquid state at the measuring temperature. The contact between 
substrate and enzyme mixture then initiates the bioluminescence 
reaction. The sandwich is put on the thermostated stage of a 
microscope (Axiophot, Zeiss, Oberkochen, Germany) within a 
light-impervious chamber. An ultrasensitive back-illuminated 
EM-CCD camera (iXonEM+ DU-888; Andor Technology PLC, 
Belfast, UK) connected to the microscope enables the registration 
of the low light bioluminescence intensity with the optics focused 
on the tissue section plane. The image signal is transferred to a 
computer for image analysis. By integrating the light emission 
intensities over a selected time interval, a two-dimensional 
density profile is obtained representing the two-dimensional 
metabolite distribution across the tissue section.
Quantification of Tissue Metabolites
Using appropriate standards, which are handled in exactly the 
same way as the tissue of interest, bioluminescence intensities can 
be transformed into absolute tissue concentrations of the respec-
tive metabolite, e.g., in micromoles per gram of tissue, which 
corresponds approximately to millimolar in solution. Routine 
standards are obtained by mixing cryo-embedding medium 
(Tissue-Tek®) with defined amounts of substrate. The frozen 
medium is then cryosectioned and processed in the same way as 
the tissue of interest.
The calibration allows for the illustration of the two-
dimensional substrate distribution in a color-coded manner, as 
indicated in Figure 1A (lower panel). This procedure is applicable 
to all metabolites specified above.
It is obvious that the light intensity is also influenced by the 
microscopic magnification, since pixel density per unit image area 
FiGURe 1 | Schematic of the procedure of induced metabolic 
bioluminescence imaging (imBi) and representative pictures from a 
human tumor sample. (A) Schematic of the procedure of induced 
metabolic bioluminescence imaging (imBI). (I) Sample preparation: the 
frozen tissue sample is precisely punctured by a small fork (a). 
Subsequently, serial cryosections are prepared (b). Each section is adhered 
on a cover glass (c) and heat inactivated (not shown). (II) A casting mold (d) 
is filled with an appropriate enzyme solution (e). Immediately before 
measurement, a frozen section on a cover glass is immersed into the 
enzyme solution (f). This “sandwich” is inserted into a thermostated 
chamber mounted on the stage of a microscope (g). The light emission is 
registered by an EM-CCD-camera connected to a computer. (III) Using an 
image analysis software (h), the raw images are processed, analyzed, 
calibrated, and, finally, expressed as color-coded images (i). Pinpricks (a) 
within the biopsy provide landmarks for a correct overlay of corresponding 
images. (B) Induced metabolic bioluminescence imaging (imBI) of lactate 
and pyruvate in a human head and neck squamous cell carcinoma 
(HNSCC) xenografted in a nude mouse. Sequential cryosections (each 
showing two punched holes for overlay) were used for hematoxylin and 
eosin (H&E) staining and imaging of lactate and pyruvate concentrations. 
For structure-associated evaluation, defined histological areas were 
delineated: tumor tissue (TU), skeletal muscle (MU), and skin (SK) [modified 
according to Walenta et al. (15)].
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and, hence, light intensity is much lower at a high magnification 
and vice versa. Other factors with impact on light intensity are 
the viscosity of the enzyme solution, the measuring temperature, 
the light integration interval, or the quantum efficiency of the 
bioluminescence reaction itself. And all these factors are mutually 
related and not at all independent of each other. In essence, the 
concert of these factors determines the sensitivity of the technique 
being on the micromolar level.
Combined Quantification and Localization 
of Metabolites
High sensitivity and high spatial resolution are contradicting 
demands, but the advantage of imBI is its versatility in adjusting 
the measuring conditions toward either resolution or sensitivity 
depending on the requirements of an actual experiment. Spatial 
resolution is restricted at a low viscosity and high temperature of 
the enzyme solution and at long light integration interval. Such 
conditions favor lateral diffusion of metabolites and enzymes 
resulting in a “smearing out” the gradients in the metabolic profiles.
For most measurements in tumor biopsies, experimental 
settings are chosen in a way that the minimum detectable sub-
strate concentration is around 100 μmol/g with a spatial linear 
resolution of around 100 μm. Keeping the former sensitivity of 
detection, the spatial resolution can be adjusted to 20 μm in imag-
ing metabolic gradients in multicellular spheroids adjusting an 
appropriate registration temperature and viscosity of the enzyme 
solution.
In our routine technology, as described above, the minimum 
detectable substrate concentration is around 100 μmol/g of viable 
tissue. Taking a given thickness of the cryosection used of 10 μm 
and a section area of 1  cm2, this corresponds to a minimum 
detectable absolute amount of substrate (i.e., the substrate content 
of one cryosection) of around 10  pg. By reducing the section 
thickness, increasing the enzyme components in the detection 
cocktails and optimizing the photon registration technique, it 
is possible to detect minimum substrate concentrations in the 
nanomolar per gram range.
Structure-Associated Metabolite 
Detection and Colocalization
Using serial sections, a section can be stained for the histological 
structure, e.g., with hematoxylin and eosin (H&E) followed by 
sections stained for the various metabolites. As outlined above, 
the “two holes technique” allows for an exact, computer-assisted 
overlay between the sections. Such an overlay makes it possible 
to detect the bioluminescence signals in a structure-associated 
way, i.e., within selected histological areas, such as viable tumor 
regions, stromal areas, or necrosis. The strategy is exemplified in 
Figure 1B.
Colocalization studies can be extended to virtually all param-
eters that can be visualized in cryosections, e.g., mRNAs detected 
by in situ hybridization, proteins assessed by immunostaining or 
functional parameters, such as blood perfusion imaged by fluo-
rescent stains or hypoxic cells identified by pimonidazole (16).
FiGURe 2 | Tumor xenografts from anti-veGF-treated mice disclose an highly glycolytic phenotype by imBi analysis. (A) Experimental layout. The tumor 
samples subjected to imBI analysis were obtained from secondary recipient mice injected with ovarian cancer cells (IGROV-1) of primary cultures from control or 
bevacizumab-treated tumors. (B) Quantification of lactate and glucose levels in tumor xenografts by imBI. Left panel: H&E staining and color-coded distributions of 
lactate and glucose in sequential cryosections from representative tumors. Since some tumors contain large central necrosis, glucose was at background levels 
within these large central areas. However, high glucose concentrations are clearly seen in the tumor periphery. This nicely illustrates the importance of structure-
associated data acquisition with imBI. The concentration values were color coded, with each color corresponding to a defined concentration range in micromolar 
per gram. Right panel: metabolite concentrations of lactate and glucose in tumors. Lactate and glucose values were calculated from n = 9 and n = 7 sections from 
anti-VEGF-treated or control tumors, respectively [reproduced from Curtarello et al. (9)].
February 2016 | Volume 6 | Article 154
Indraccolo and Mueller-Klieser imBI: Applications in Tumor Angiogenesis
Frontiers in Oncology | www.frontiersin.org
APPLiCATiOnS OF imBi in THe FieLD OF 
TUMOR AnGiOGeneSiS
Induced metabolic bioluminescence imaging proved to be an 
extremely useful technique to investigate modulations in the con-
centration of metabolites in tumors treated with antiangiogenic 
drugs (Figure 2). In tumor xenografts, we observed a dramatic 
reduction in glucose and ATP levels in the tumor microenviron-
ment following anti-VEGF therapy (12). Such changes led us 
to speculate that glucose-addicted tumors could be particularly 
vulnerable to the effects of VEGF blockade. In fact, the amount 
of necrotic area in the highly glycolytic tumors was much larger 
compared with values found in poorly glycolytic tumors, thus 
connecting a metabolic trait of tumor cells to an histological 
pattern of response to VEGF neutralization.
It is currently unknown whether this intriguing observation 
might hold true also in the case of other angiogenesis inhibitors 
acting downstream of the VEGF receptor, such as tyrosine kinase 
inhibitors, nor whether the findings can be generalized to tumors 
grown in different organs/tissues, as tissue-specific features of 
the microvasculature could also impact on the outcome of VEGF 
blockade. Despite these limitations, it should be acknowledged 
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that imBI was key to enable us to formulate the initial hypoth-
esis, To further validate it in translational studies, it will prob-
ably be necessary to replace assessment of the tumor gylcolytic 
phenotype by imBI  –  which requires frozen tissues  –  with an 
appropriate in situ marker of glycolysis, such as monocarboxy-
late transporter 4 (MCT4), which could be assessed by routine 
immunohistochemistry staining in hundreds of formalin-fixed 
paraffin-embedded (FFPE) tumor samples.
In addition, imBI could be used to perform metabolic clas-
sification of tumors and compare in vitro and in vivo assessment 
of metabolic features, as we recently showed (17). Given the 
adequate spatial resolution of this technique (~100 μm), and the 
possibility of matching metabolic parameters with histology, it 
can be anticipated that imBI could be utilized to describe both 
inter-tumor and intra-tumor metabolic heterogeneity, as first step 
of an in-depth characterization of tumor regions with different 
abundance of lactate or other measurable metabolites.
In summary, imBI has a clear role in preclinical studies of 
tumor angiogenesis in that it can (I) be utilized to investigate 
metabolic modulations associated with antiangiogenic therapy 
and (II) can enable metabolic classification of tumors and detect 
metabolic heterogeneity.
COnCLUDinG ReMARKS
A more comprehensive understanding of metabolic perturba-
tions caused by antiangiogenic drugs in tumors might represent 
a first step toward improvement of therapeutic efficacy, which is 
currently blunted by adaptive resistance (18, 19). Along this line, 
recent studies reported perturbations in lipid metabolism under 
hypoxic conditions. Bensaad et al. described increased fatty acids 
uptake and accumulation of lipid droplets in the cytoplasm of 
tumor cells incubated under hypoxic conditions or in tumors 
treated with bevacizumab (20); this phenomenon was associated 
with hypoxia inducible factor (HIF)-1α-driven expression of fatty 
acids binding proteins 3 and 7 in tumor cells. Moreover, Huang 
et al. observed that hypoxic stress regulates lipid metabolism in 
hepatocellular carcinoma cells. Specifically, these authors reported 
that HIF-1-mediated suppression of medium and long-chain 
acyl-CoA dehydrogenases and fatty acid oxidation leads to fatty 
acids accumulation and is critical for cancer progression (21). 
As antiangiogenic therapy generally increases tumor hypoxia, in 
future studies, it will be important to further investigate whether 
anti-VEGF therapy causes perturbations in lipids.
In the long-term, metabolic changes caused by anti-VEGF 
therapy could indeed represent an opportunity for new 
metabolism-targeting drugs. In this regard, our previous studies (9, 
12) showed that tumor xenografts formed by different tumor cell 
lines have marked metabolic differences, which would likely convey 
limited therapeutic response to glycolysis inhibitors (Figure 2). In 
contrast, after antiangiogenic therapy tumors become homogene-
ously highly glycolytic and glucose addicted, which could render 
them more responsive to glycolysis-targeting drugs. In a related 
study, Sounni et al. demonstrated that breast tumors treated with 
antiangiogenic tyrosine kinase inhibitors (sunitinib) in the post-
treatment time undergo a metabolic shift involving increased lipid 
synthesis and have improved response to the lipogenesis inhibitor 
orlistat (22). Altogether, these observations suggest that sequential 
combination of antiangiogenic drugs and certain metabolism-tar-
geting drugs might represent a new therapeutic concept for cancer.
With regard to imBI, its successful application in the field of 
glucose metabolism should encourage set-up of new protocols 
for the detection of additional metabolites, such as amino acids 
and fatty acids. The imBI technique is indeed appropriate for 
the detection of any metabolite that can be enzymatically linked 
to the NAD(P)H+H+ redox system. This offers the opportunity 
to analyze a broad spectrum of metabolic pathways beyond 
glycolysis. For example, lipid metabolism may be investi-
gated by quantifying l-3-hydroxyacyl-CoA with imBI using 
hydroxyacyl-CoA-dehydrogenase as an enzymatic link. Similarly, 
ketogenesis may be studied by the detection of acetoacetate using 
beta-hydroxybutyrate dehydrogenase.
In conclusion, in the near future, it will be feasible to use imBI 
to achieve an integrated view on serial tumor sections of the 
metabolic pathways active in individual tumors and their varia-
tions following targeted therapies.
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